Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T12:51:40.100Z.
Calculation as of: 2026-10-06T12:51:40.100Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$244.25M
EV/FCF Ratio
3.55x
TTM Avg
5.14x
3Y Avg
5.14x
5Y Avg
5.14x
Market Cap
$248.21M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$251.64M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.30M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $245.65M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 3.55x | 5.14x | 5.14x | 5.14x |
| InflaRx N.V. (IFRX)vs › | $247.45M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.89M | 25.66x | 23.33x | 20.20x | 22.09x |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | 442.97x | 210.95x | 227.91x | 182.13x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
